Pharmafile Logo
Pharmafocus logo
Advanced Search

Mavatar announces research collaboration with Sobi

January 6, 2026
Research and Development Immunology, Mavatar, Rare Diseases, sobi

Mavatar has announced the initiation of a non-clinical research collaboration with Sobi, using Mavatar’s technology to generate data insights into …

News

DemeRx announces completion of alcohol use disorder treatment trial

January 5, 2026
Research and Development DemeRx, alcohol use disorder

DemeRx has announced the successful completion of its phase 1 study of DMX-1001 (oral noribogaine) in the treatment of alcohol …

News

Andera Partners leads financing for asthma treatment company Spiro Medical

January 5, 2026
Sales and Marketing Andera Partners, Asthma & COPD, Spiro Medical

Andera Partners, a private equity firm, has announced its leadership of a $67m series A financing round in Spiro Medical, …

News

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025
Research and Development Bio-Thera, Immunology, Stada

STADA and Bio-Thera’s Gotenfia (golimumab), a biosimilar of Janssen’s Simponi, has received a positive opinion from the European Medicines Agency …

News

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025
Manufacturing and Production Hepatology, Norgine, Vir Biotechnology

Norgine has announced its exclusive licensing agreement with Vir Biotechnology, under which Norgine will commercialise the combination of tobevibart and …

News

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025
Incyclix, board of directors

Incyclix Bio, a cell cycle control company, has announced the appointment of Kimberly Blackwell to its Board of Directors as …

Appointment

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025
General Manager Europe and International, Hansa Biopharma, vice president

Hansa Biopharma, a commercial-stage biopharmaceutical company focusing on rare immunological conditions, has announced the appointment of Max Sakkajja as Vice …

Appointment

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025
Regulatory Affairs, Research and Development Asthma & COPD, GSK

GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) …

News

Gilead’s HIV treatment meets primary trial endpoint

December 16, 2025
Research and Development Gilead, HIV/AIDS

Gilead has announced positive topline results from its phase 3 ARTISTRY-2 trial, which evaluated a combination of bictegravir and lenacapavir …

News

EIFO and FSG invest in Fida Biosystems to accelerate growth

December 15, 2025
Sales and Marketing EIFO, FSG, Fida Biosystems

The Export and Investment Fund of Denmark (EIFO) and Fåhraeus Startup and Growth Fund (FSG) have invested 5m euros in …

News

BioPhorum announces acquisition of Inspired Pharma

December 15, 2025
Mergers and Acquisitions BioPhorum, Inspired Pharma

BioPhorum, a global pharmaceutical collaboration group, has announced the acquisition of Inspired Pharma, a provider of specialist pharmaceutical training. The …

News

Evotec and Bayer announce new kidney disease study

December 11, 2025
Research and Development Bayer, Evotec, Nephrology

Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney disease, stemming from their previous …

News

Actithera appoints Darshan Dalal as Chief Medical Officer

December 11, 2025
Actithera, chief medical officer

Actithera has announced the appointment of Dr Darshan Dalal as its new Chief Medical Officer. Dalal brings over 15 years …

Appointment

Pace appoints Ken Beyer as CEO

December 10, 2025
CEO, Pace Analytical

Pace, a science and technology company specialising in environmental and life sciences laboratories, has announced the appointment of Ken Beyer …

Appointment

EpilepsyGTx raises $33m for focal refractory epilepsy gene therapy

December 10, 2025
Research and Development EpilepsyGTx, Neurology, epilepsy

EpilepsyGTx, a biotechnology company researching and developing gene therapies for the treatment of refractory epilepsy, has announced $33m raised in …

News

Breast Cancer Now study to explore personalised drug doses

December 9, 2025
Research and Development Breast Cancer Now, Oncology

Breast Cancer Now has announced a new study to evaluate whether personalised drug doses could improve quality of life for …

News

insitro appoints Stephen Hitchcock and Vijay Pande as scientific advisors

December 9, 2025
insitro, scientific advisor

insitro, an AI therapeutics company, has announced the appointment of Stephen Hitchcock and Vijay Pande as scientific advisors. Hitchcock brings …

Appointment

STADA appoints Ole Wendler Pedersen as Executive VP Legal and General Counsel

December 8, 2025
Executive VP Legal and General Counsel, Stada

German pharmaceutical company STADA has announced the appointment of Ole Wendler Pedersen as its new Executive Vice President Legal and …

Appointment

UCB presents positive results for fenfluramine in CDKL5 deficiency disorder

December 8, 2025
Research and Development Neurology, UCB, epilepsy

UCB has announced positive results from its phase 3 GEMZ study, showing that fenfluramine can significantly reduce the frequency of …

News

Teva announces positive results from trial of AJOVY for migraine

December 5, 2025
Research and Development Neurology, Teva, migraine

Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its treatment for chronic (CM) and …

News
The Gateway to Local Adoption Series

Latest content

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026

PSI appoints David Allen as Country Manager for Canada

January 22, 2026

Qureight appoints Steven Bishop as Chief Medical Officer

January 21, 2026

Pierre Fabre Laboratories and Iktos announce oncology collaboration

January 21, 2026

Qureight appoints Rebecca Simmons as Chief Operating Officer

January 20, 2026